Trial Profile

Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX) to Children 15 Months of Age

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hepatitis A vaccine inactivated (Primary) ; Measles mumps and rubella virus vaccine; Varicella zoster virus vaccine live
Indications Chickenpox; Hepatitis A; Measles; Mumps; Rubella
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

25 May 2011 Results published in the Pediatric Infectious Disease Journal.
12 Feb 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
12 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com